Skip to content

Advertisement

  • Review
  • Open Access

The molecular mechanism of ovarian granulosa cell tumors

Journal of Ovarian Research201811:13

https://doi.org/10.1186/s13048-018-0384-1

  • Received: 28 November 2017
  • Accepted: 30 January 2018
  • Published:

Abstract

Over these years, more and more sex cord-stromal tumors have been reported. Granulosa cell tumor (GCT) is a rare tumor in ovaries, accounts for 2% to 5% of ovarian cancers. The main different feature of GCTs from other ovarian cancers is that GCTs can lead to abnormally secreted hormones (estrogen, inhibin and Müllerian inhibiting substance). The GCT is divided into two categories according to the age of patients, namely AGCT (adult granulosa cell tumor) and JGCT (Juvenile granulosa cell tumor). AGCT patients accounts for 95%. Although the pathogenesis is not clear, FOXL2 (Forkhead box L2) mutation was considered as the most critical factor in AGCT development. The current treatment is dominated by surgery. Target therapy remains in the adjuvant therapy stage, such as hormone therapy. During these years, other pathogenic factors were also explored, such as PI3K/AKT (phosphatidylinositol-3-kinase; serine/threonine kinase), TGF-β (Transforming growth factor beta) signaling pathway, Notch signaling pathway, GATA4 and VEGF (vascular endothelial growth factor). These factors and signaling pathway play important roles in GCT cell proliferation, apoptosis, or angiogenesis. The purpose of this review is to summarize the possible pathogenic factors and signaling pathways, which may shed lights on developing potential therapeutic targets for GCT.

Keywords

  • GCT
  • FOXL2
  • PI3K/AKT signaling
  • TGF-β signaling
  • Notch signaling

Background

Granulosa cell tumor (GCT) is the most common sex cord-stromal tumor that stem from granulosa cells. GCT accounts for 2% to 5% of all ovarian cancers and can be divided into two subtypes according to the differences of the age of patients, clinical and histopathologic features [1]. About 95% of GCT belong to the adult granulosa cell tumors (AGCTs), and others are juvenile granulosa cell tumors (JGCTs). JGCT only occurs in people who are younger than 30 years old with the features of hypoestrogenism and abnormal abdominal mass [2, 3]. Clinical features of AGCT include abnormal uterine bleeding in postmenopausal patients and menometrorrhagia in youngers. Some reports also indicated that patients were with stopping ovulating symptom [4]. The incidence of GCT is around 0.47 to 1.6 per 100,000. The main risk factors of GCT include nulliparity, fatness, oral contraceptives and family cancer history. From the cancer databases in Finland, Iceland, Norway and Sweden, the GCT onset showed scattered feature. There was no increasing trend over the 60 years [5]. Abnormal cell cycle is related to the occurrence and development of cancers. The recent studies provided powerful evidences that fork head box protein L2 (FOXL2), PI3K/AKT signaling pathway, TGF-β signaling pathway, Notch signaling pathway and etc. were involved in granulosa cell tumor through influencing cell proliferation and apoptosis [610].

In the development of GCT, a variety of cell signaling pathways, such as TGF-β, Notch and PI3K/AKT, are involved. In fact, these signal pathways are not isolated, but make up a complex network and contribute to the formation and development of GCT. FOXL2 is the most important mutant gene in GCT formation. Studies showed that FOXL2 is involved in the TGF-β pathway. For example, FOXL2 mutation has negative effect on SMAD3 (drosophila mothers against decapentaplegic protein) activation by interacting with BMPs, follistatin and activin A [11]. FOXO1/3 (forkhead box O1/3) also inhibited SMAD3 [12]. The interaction between Notch signaling and PI3K/AKT were also proved [13]. In the following sections, we will summarize the influence of different cell signaling network on GCT.

FOXL2

Forkhead transcription factor 2 (FOXL2) is a transcription factor. The gene is 2.7 kb long and encodes 376 amino acids, which locates at human chromosome 3q23. The sequence of FOXL2 is highly conserved. It is mainly expressed in ovarian granulosa cell and pituitarium. FOXL2 is the first confirmed autosomal gene that maintains normal function of ovary, and it is also a marker of sexual selection and development. FOXL2 knockout mouse model showed sex reversal [14]. Further studies showed that FOXL2 regulated the ovarian granulosa cell proliferation, follicle development and ovarian hormones synthesis [14].

In 2009, a breakthrough of AGCT, using the whole-transcriptome paired-end RNA sequencing, showed that a somatic missense mutation (402C»G) occurred in four different AGCT samples at C134W (amino acid position 134) [15]. From the published results, the mutation exists in more than 97% of AGCT, and it is rarely detected in other ovarian cancer [16]. Some reports showed that the expression of FOXL2 was also downregulated in aggressive JGCT [17, 18]. These studies make FOXL2 as one possible pathognomonic defining feature. The mechanism of mutant FOXL2 in GCT was also widely explored. Some studies showed that prominent serine 33 (S33) phosphorylation of FOXL2, which is induced by GSK3β, was detected in C134W mutation. The phosphorylation modification of FOXL2 contributes to the growths of GCTs [19, 20]. The growth of GCT was proportional to the S33 phosphorylation status, and GSK3β inhibitor might serve as an effective intervention for GCT therapy [19].

Some studies examined the transcriptional targets of mutant FOXL2. Wile-type FOXL2 plays a key role in inhibiting granulosa cell proliferation and promoting apoptosis [21]. However, mutant FOXL2 downregulated the INHA, one of a proliferative signaling ligand [22]. Death signaling mediators, TNF-R1 (Tumor necrosis factor receptor 1) and FAS, were also decreased [23]. Caspase 8, BID and BAK determine the FOXL2 depended granulosa cell apoptotic pathway, but mutant FOXL2 was unable to elicit the apoptotic signaling responses [24]. In addition, mutant FOXL2 has been shown to reduce GnRH receptor expression, thus conferring resistance to GnRH-induced cell apoptosis [25]. Follistatin is mainly expressed in granulosa cells of developing follicles and it binds to activin A to block activin A-stimulated granulosa cells proliferation [26]. Mutant FOXL2 suppresses follistatin expression and leads to increased cells proliferation and tumor formation [6, 11]. Furthermore, FOXL2 mutation also leads to TGF-β signaling pathway deregulation [23].

More and more clinical data show that FOXL2 mutation is the main factor in AGCT So, understanding the FOXL2 regulation mechanism is instrumental to develop new prevention and therapy methods.

Notch signaling pathway

Notch signaling is highly conserved in evolution, which plays critical role in organisms’ development. In mammalian, there are four Notch receptors, Notch1 to 4, There are three domains in Notch receptors, including functional extracellular (NECD), transmembrane (TM) and intracellular (NICD). Five Notch ligands, Jagged-1, Jagged-2, Delta-like-1 (DLL1), Delta-like-3 (DLL3) and Delta-like-4 (DLL4) had been identified [27, 28]. Both the Notch ligands and the receptors are transmembrane proteins. When ligands bind receptors, Notch receptors become susceptible to proteolytic cleavage mediated by secretase complex, which releases the intracellular domain of Notch. NICD enters nucleus and forms a complex with recombination signal binding protein-Jk, which contains a DNA binding domain. The complex regulates Myc, P21, HES family, Cyclin D3 and other Notch target genes. The deregulation of Notch signaling has been proved to be related to several cancers [27]. Studies showed that DLL4, Jagged-1, Notch1 and Notch4 were highly expressed in KGN cells (FOXL2-mutated granulosa tumor cell line), compared with granulosa-lutein cells. DAPT, an inhibitor of γ-secretase, was used to treat KGN cells and the inhibition of Notch system lead to lower proliferation and viability, as well as estradiol and progesterone secretion of KGN cells [13, 29]. Several apoptotic parameters such as BAX, BCLXs, PARP and caspase eight cleavages were increased after DAPT treatment. The interaction of Notch signaling and PI3K/AKT signaling were also been proved in the process. AKT phosphorylation was decreased and PTEN (phosphatase and tensin homolog deleted on chromosome ten) protein was increased after Notch signaling inhibition [13]. More studies are needed to demonstrate that Notch signaling would be potential therapeutic targets for AGCT.

TGF-β signaling pathway

TGF-β super family is composed of 30 different growth and differential factors, including TGF-βs, activin, inhibin and BMPs (bone morphogenic proteins) [30]. TGF-β related signaling pathway plays critical roles in regulating stem cell cycle, organ development and immune cells through regulating cell proliferation, differentiation, and death [31]. SMAD proteins are general signaling pathway mediated proteins in TGFβ signaling network [32]. When the signaling pathway is abnormally activated, it may lead to diseases.

Activin and inhibin

Inhibin and activin are two hydrophilic non-steroid substances and are mainly synthesized by pituitary cells and ovarian granulosa cells. They have two α and β subunits. α and β subunits are encoded by different genes respectively. The β subunit consists of five different types of homologous compositions, βA, βB, βC, βD and βE. βA and βB units can form three kinds of activins linked by a disulfide bond, including activin A (βA-βA), B (βB-βB) and C(βA-βB) [33]. Inhibins were composed of Inhibin βA, βB units shared with activins, and a unique α-subunit (INHA), inhibin A (α-βA) and inhibin B (α-βB) [34]. Activins function via combining with activin-type 1 receptors and activin-type 2 receptors. The complex can activate SMAD2/3 through phosphorylation [35]. While inhibins carry out their biological role by antagonizing activin pathway [36].

Inhibin was first defined in 1932 [37]. As one gonadal hormone, Inhibin played important role in regulating folliculogenesis, steroidogenesis and FSH production [34]. Inhibin was also defined as a critical negative regulator of gonadal stromal cell proliferation and was identified to have tumour-suppressor activity [38]. Inhibin-α can inhibit granulosa cell proliferation and promotes apoptosis [39]. High expression of inhibin-α subunit exists in most human gonadal cancers. Loss of inhibin-α can lead to more aggressive GCT by using INHA knockout mice [38, 4042]. As to the two subtypes of inhibin, studies showed that almost all the GCT patients had higher level of inhibin B, and over synthesized inhibin A was also detected in some cases [43]. Lower inhibin sensitive is also related to GCT development and tumor metastasis. Betaglycan or p120 was identified as inhibin receptors, which is associated with the type II or type I activin receptor subunits (ActR), respectively [44]. Studies showed that only p120 was especially high in GCT patients [44]. Not only in GCT, but also other types of ovarian tumor, abnormal elevated inhibin had been proved [43].

Activins have critical functions in genital system. Activin synthesized by pituitary gonadotrophic cells decreases the activation of luteotropic and promotes the expression of follicle stimulating hormone receptors, so it enhances the follicle development [45]. Activin binds to type II receptors, and then recruits and phosphorylates of type I receptor ALK4, which phosphorylates both SMAD2 and SMAD3 proteins. GCT cells show high inhibinβA subunit expression level and the proliferation rate was positively correlated with a high activin A to inhibin A ratio, suggesting that the tumor cells stimulated their growth through an activin A autocrine signaling pathway [46]. In GCT patients, abnormal activin receptors may lead to failure of granulosa cell apoptosis [26]. There are controversies about GCT markers. Early studies suggested that inhibin B and activin A were elevated in GCT patients. But recently it has also been suggested that inhibin B is more specific than activin A [47, 48]. In fact, activin still does not have the significance of large-scale application in the diagnosis and prognosis of GCT. The healthy activin levels are also increased significantly in postmenopausal women and ovarian cancer patients. The relationship between GCT and elevated inhibin is still unclear. The clinical application of inhibin as a tumor marker remains controversial. However, the clinical data and available studies suggest that the inhibin test may be used as part of a GCT screening and be used for disease prognosis [49, 50].

BMPs

Bone morphogenetic proteins (BMPs) are a group of at least 20 growth factors. They were firstly found in ostosis as induction proteins [51]. BMPs are multi-functional growth factors and have been implicated in a variety of functions. BMPs induce the formation of both cartilage and bone. BMPs also play a role in a number of non-osteogenic developmental processes, such as epidermal induction, inhibition of limb bud and myogenesis [52, 53]. BMPs can inhibit the growth of normal cells and human colon, prostate and breast cancer cell lines when the BMP signal components are complete. In addition, the BMP pathway was inactivated in 70% of colorectal cancers. The lack of two BMP type I receptors, Bmpr1a and Bmpr1b in the ovarian granulosa cells of mice were involved in the development of GCT [54]. The expression of Myc, cyclin D2 and cyclinE2 was highly increased in BMPR1a and BMPR1b double knockout mice, which result in the promotion of granulosa cell tumor proliferation [55]. BR-SMADs represented SMAD1/5/9 signal via interacting with BMP receptors. The study showed GCT development in BR-SMADs conditional knock out mice [56]. The studies in KGN cell line confirmed that FSH increased the expression of BMP type 1 receptors (BMPR1A/B) and BMP type 2 receptors (BMPR2). BMP6/7 induced phosphorylation of SMAD1/5/8. What’ more, FSH also promoted SMAD1/5 expression, while it reduced the inhibitory SMAD, SMAD6/7 expression [57].

As the upstream ligand for BMPR, BMP-2 is proved to be greatly associated with follicle formation. BMP7 was highly expressed in granulosa cell. Studies proved that BMP7 induced a rise rate in DNA synthesis and proliferation in granulosa cells [58, 59]. Studies showed that BMP15 was involved in polycystic ovary syndrome (PCOS). BMP15/SMAD1 may regulate granulosa cell apoptosis, which expression were significantly decreased in PCOS [60]. However, the relationship between BMPs and GCT is still unclear.

AMH

AMH is a regulator in sexual differentiation and it was also considered as an inhibitor in ovary cancer development. Normal granulosa cells and GCT both synthesize AMH. In human GCT, there was a controversy of high serum but low tissue AMH level. But it had been confirmed that serum AMH levels were positively correlate with the GCT size [6163]. It can be speculated that AMH in the tumor microenvironment was lower than normal level [61]. AMH participates in the BMP signaling pathway to inhibit GCT formation, and lower expression of AMH reduced the activation of BMP signaling components. In addition, Extrinsic AMH reduced the number of KGN cells and primary GCT cells. It was proved that overexpression of AMH induced an increased activation of caspase-3 and subsequent apoptosis [64].

SMAD

SMADs are intracellular proteins, which occupy critical position in transducing TGF-β signaling from the receptors on cell surface to nucleus. According to the structures, SMADs divided in to three sub-families, R-SMAD (receptor-regulated type), Co-SMAD (common-mediator type) and I-SMAD (inhibitory type) [65]. In follicle development, many studies have showed these factors have co-operative functions.

SMAD 4 is the common mediator, is also a well-known tumor suppressor in human [66]. However, no ovarian tumors develop in SMAD4loxp/loxp AMHR2 Cre mice. The deletion of SMAD4significantly disturbed the reproduction ability of mice. The lack of SMAD4 also promoted luteinization [67]. SMAD4 is necessary for FSH synthesis. Studies also indicated that SMAD4 played its role with FOXL2. When SMAD4 and FOXL2 were double deleted, FSH synthesis was almost stopped and females were sterile. The phenotype is similar to Fshb-knockout mice [68]. In ovulation period, SMAD4 was necessary in ERK1/2 activation [69]. During ovary development, the expression of SMAD4 was increased with the growth. SMAD4 silencing can increase the expression of CDK1 and CCNB2, suggesting that SMAD4 can also regulate cell cycle [70, 71].

Conditional deletion of SMAD1 and SMAD5 in ovarian granulose cells causes metastatic granulose cell tumors (GCTs) in female mice and phenocopies human juvenile GCTs (JGCTs) [54]. SMAD1/4/5 triple knockout mice showed increased survival rate and smaller tumor size, means that SMAD4 regulated signaling pathway may be a cancer promotor.

Both SMAD2 and SMAD3 are considered as important factors in ovarian development and functions. The ability of fecundity was reduced in the SMAD3-type (SMAD3-/-) mice, which also showed poor granulosa proliferation [72]. The TGF β-SMAD2/3 pathway is active in JGCTs. TGF-β may play as a promoting factor in JGCT, because the related signaling pathway can inhibit cell apoptosis [73]. Growing GCT cells expressed high levels of nuclear SMAD3 [46]. In KGN cell line, when NFκB expression is inhibited, the SMAD3 expression is also reduced, while SMAD3 is been proved overexpressed in AGCT [74]. SMAD3 interacted with FOXL2 and GATA4 modulated cell viability and apoptosis in ovarian granulosa cell tumour cells through regulating the expression of CCND2 [7, 75].

SMADs are critical regulation proteins in TGF-β family and they are significant in TGF-β signaling dynamic accommodation between cell plasma and nucleus. But the complete process is not clear now. The future study need to concentrate on the co-regulation among different SMADs and other regulating factors in GCT.

PI3K/AKT signaling pathway

It has been demonstrated that activation of AKT pathway via PI3K is highly related to tumorigenesis. In ovarian cancers, AKT signaling blocks cell apoptosis through inhibiting FOXO1 and Bcl-2 proteins transcription [76, 77]. Forkhead box O1/O3, are the O class of the forkhead family. FOXO1 locates at chromosome 13, while FOXO3 locates at chromosome 6. In normal condition, FOXOs combine with the promotor of P27KIP1. P27 (Cyclin-dependent kinase inhibitor 1B) is an inhibitor in cell cycle. Once FOXOs were phosphorylated by AKT, the transcription of p27 would be influenced and lead to abnormal cell proliferation. [78]. Evidences showed FOXO1a influenced p27 nuclear localization and inhibited granulosa cell proliferation [79]. TRAIL has the effect of high efficiency and rapid induction of apoptosis of tumor cells and virus infected cells, but not normal cells [80]. FOXOs can also regulate TRAIL [81]. The knockdown of TRAIL obviously reduced the apoptosis induced by FOXO3 [82]. FOXO1/3 double knock out mice have high risk in getting GCT [83].

PTEN is one negative regulator of PI3K signaling and its mutation is very common in human cancers. PTEN is an important tumour suppresser. Studies indicated that lower PTEN expression levels was related to cancer development [84]. The expression of PTEN in ovarian cancer was negatively correlated with clinical stage, differentiation and VEGF expression. The overall survival of PTEN-positive patients was significantly longer than that of negative expression [85]. The depletion of PTEN and FOXO1/3 has a synergistic effect in GCT development, but the single knockout PTEN mice rarely developed to GCT [83]. In ovaries, PTEN mutation leaded to over-phosphorylation of AKT. In addition, FOXOs can promote PTEN transcription, suggesting that there exists a negative feedback among them [81, 86]. In addition, uncontrolled PI3K activity within oocytes irreversibly transforms granulosa cells into GC tumors through perturbed local cell communication [46]. Lague et al. provided powerful evidence for the role of the dysregulation of the PI3K/AKT pathway in the pathogenesis of GCTs by means of a Ptenflox/flox, Amhrcre/+ mouse model. Activation of WNT/CTNNB1 signaling causes late-onset GCT development. However, activation of both the PI3K/AKT and WNT/CTNNB1 pathways in the granulosa cell. Had 100% penetrance and extremely rapid growth and the ability to spread [87].

Others

GATA4

GATA4 belongs to the GATA family of zinc finger transcription factors. In human, it locates at 8p23.1. The current study indicated that GATA4 played key role in embryogenesis and cardiac development. GATA4 mutations can lead to heart disease due to abnormal fold or other embryogenic failure in heart. Based on statistics of clinical GCT samples, overexpression of GATA-4 is associated with higher recurrence and more aggressive of GCT [63]. Evidences show GATA4 can regulate GCT cell apoptosis and proliferation by activating Bcl-2 and cyclin D2, respectively [88, 89]. Overexpressing GATA4 protects GCTs from TRAIL-induced apoptosis in KGN cells [90]. In other species, like dogs, GATA-4 is also the GCT markers [91]. In previous sections, we introduced the role of SMAD3 and FOXOL2. Studies showed that FOXL2, GATA4, and SMAD3 expression patterns overlap in the fetal and adult ovary. The three factors co-operatively modulate the cell viability and apoptosis in ovarian granulosa cell tumour cells through regulating the expression of CCND2 [7].

VEGF

Vascular endothelial growth factor played important role in cancer development, as a cell factor that mainly regulates vasculogenesis. VEGF and its receptors were hugely expressed in GCTs [92, 93]. In anti-VEGF therapy, some case reports showed that bevacizumab was benefited to recurrent GCT patients [93]. VEGFR1 normally be considered as a decoy receptor and it showed unobvious phosphorylation when combined with VEGF [94]. VEGFR2, was usually seen as the main mediator of VEGF [95]. The expression levels of VEGFR2 were higher in GCT patients, while VEGF1 expression levels showed no increase trendy [93].

Conclusion

GCT incidence of ovarian cancer accounts for about 2% to 5%, while the prognosis is usually better. Five-year survival rate is up to 90%. High recurrent rate is the most critical factor for GCT death. At present, the most important problem lies in the early diagnosis and prevention of recurrence. FOXL2 mutation is the main cause of GCT, while other factors also contributed to it, such as GATA4, SMAD, VEGF, PI3K/AKT, AMH and TGF-β.The \treatment for GCT includes surgery, radiotherapy, chemotherapy and hormone therapy. Studies showed that hormones play a critical role in the pathogenesis and treatment of GCT, especially in some ineffective cases for radiotherapy and chemotherapy. However, the serious adverse effects were followed. New treatment strategies need to be explored. The employment of anti-VEGFA antibody in mouse model successfully slowed the tumor development through inhibiting the tumor cell proliferation [96]. Other studies also demonstrated anti-VEGF (or VEGFR) had conspicuous function in inhibiting GCT development [97, 98]. As for chemotherapy, drug targeting in critical signaling pathways can increase efficiency. Chemokine (C-C motif) ligand 5 (CCL5) can reduce the toxic of cisplatin by increasing AKT phosphorylation level [99, 100]. GLS (glutaminase) is the key metabolic enzymes of glutaminolysis, which is highly expression in tumors. The inhibition of GLS1 leaded to decreased expression of phosphorylated STAT3, which provided an idea in overcoming the resistance of PI3K inhibitor [100, 101]. Targeted therapy for signaling pathways can effectively prevent the recurrence of GCT and reduce the resistance of chemotherapeutic drugs. Many studies have shown that GCT-related signaling pathways and pathogenic genes are closely linked, and the link between these signaling pathways is unclear. As shown in Fig. 1, we summarized these related signaling pathways network. Certainly, surgery is still the most important treatment. Targeting drugs for signal pathway in the subsequent chemotherapy can significantly improve the survival rate of patients. Future research should further focus on exploring the molecular mechanisms of GCT and developing targeted medicines. Prevention of recurrence of GCT will significantly improve patient survival.
Fig. 1
Fig. 1

Schematic representation of the cell signaling pathways in GCT development. PI3K, phosphatidylinositol-3-kinase; AKT, serine/threonine kinase; FOXO 1/3, forkhead box O1/3; AMH, anti-Mullerian hormone; BMP, bone morphogenetic protein; SMAD, drosophila mothers against decapentaplegic protein; FOXL2, forkhead transcription factor 2; Rb, retinoblastoma protein; Bcl-2, B-cell lymphoma 2

Abbreviations

AGCT: 

Adult granulosa cell tumor

AKT: 

Serine/threonine kinase

AMH: 

Anti-Mullerian hormone

Bcl-2: 

B-cell lymphoma 2

BMP: 

Bone morphogenetic protein

DLL1: 

Delta-like-1

DLL3: 

Delta-like-3

DLL4: 

Delta-like-4

FOXL2: 

Forkhead box L2

FOXO 1/3: 

Forkhead box O1/3

GCT: 

Granulosa cell tumor

GLS: 

Glutaminase

INHA: 

Inhibin α-subunit

JGCT: 

Juvenile granulosa cell tumor

PI3K: 

Phosphatidylinositol-3-kinase

PTEN: 

Phosphatase and tensin homolog deleted on chromosome ten

Rb: 

Retinoblastoma protein

SMAD: 

Drosophila mothers against decapentaplegic protein

TGF-β: 

Transforming growth factor beta

VEGF: 

Vascular endothelial growth factor

Declarations

Acknowledgements

Not applicable.

Funding

This study was supported by National Natural Science Foundation of China (81601242) and Natural Science Foundation of Jiangxi province (20161BAB215199).

Availability of data and materials

Not applicable (review article).

Authors’ contributions

JL executed and drafted the manuscript, RB and SP made critical discussion about the study. CZ designed the study. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable (review article).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Joint programme of Nanchang University and Queen Mary University of London, Nanchang, China
(2)
Department of Gynecology and Obstetrics, Jiangxi Provincial People’s Hospital, Nanchang, China
(3)
Department of Cell Biology, School of Medicine, Nanchang University, Nanchang, Jiangxi, 330006, People’s Republic of China

References

  1. Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol. 2003;21:1180–9.View ArticlePubMedGoogle Scholar
  2. Rao AC, Kishore M, Monappa V. Juvenile Granulosa cell tumour: anaplastic variant with omental deposits. J Clin Diagn Res. 2016;10:ED01–3.PubMedPubMed CentralGoogle Scholar
  3. Kalfa N, Philibert P, Patte C, Thibaud E, Pienkowski C, Ecochard A, Boizet-Bonhoure B, Fellous M, Sultan C. Juvenile granulosa-cell tumor: clinical and molecular expression. Gynecol Obstet Fertil. 2009;37:33–44.View ArticlePubMedGoogle Scholar
  4. Obendorf DL. Pathology of the female reproductive tract in the koala, Phascolarctos Cinereus (Goldfuss), from Victoria, Australia. J Wildl Dis. 1981;17:587–92.View ArticlePubMedGoogle Scholar
  5. Bryk S, Pukkala E, Martinsen JI, Unkila-Kallio L, Tryggvadottir L, Sparen P, Kjaerheim K, Weiderpass E, Riska A. Incidence and occupational variation of ovarian granulosa cell tumours in Finland, Iceland, Norway and Sweden during 1953-2012: a longitudinal cohort study. BJOG. 2017;124:143–9.View ArticlePubMedGoogle Scholar
  6. Leung DT, Fuller PJ, Chu S. Impact of FOXL2 mutations on signaling in ovarian granulosa cell tumors. Int J Biochem Cell Biol. 2016;72:51–4.View ArticlePubMedGoogle Scholar
  7. Anttonen M, Pihlajoki M, Andersson N, Georges A, L'Hote D, Vattulainen S, Farkkila A, Unkila-Kallio L, Veitia RA, Heikinheimo M. FOXL2, GATA4, and SMAD3 co-operatively modulate gene expression, cell viability and apoptosis in ovarian granulosa cell tumor cells. PLoS One. 2014;9:e85545.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Farkkila A, Andersson N, Butzow R, Leminen A, Heikinheimo M, Anttonen M, Unkila-Kallio L. HER2 and GATA4 are new prognostic factors for early-stage ovarian granulosa cell tumor-a long-term follow-up study. Cancer Med. 2014;3:526–36.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Hua G, He C, Lv X, Fan L, Wang C, Remmenga SW, Rodabaugh KJ, Yang L, Lele SM, Yang P, et al. The four and a half LIM domains 2 (FHL2) regulates ovarian granulosa cell tumor progression via controlling AKT1 transcription. Cell Death Dis. 2016;7:e2297.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Chang HM, Cheng JC, Taylor E, Leung PC. Oocyte-derived BMP15 but not GDF9 down-regulates connexin43 expression and decreases gap junction intercellular communication activity in immortalized human granulosa cells. Mol Hum Reprod. 2014;20:373–83.View ArticlePubMedPubMed CentralGoogle Scholar
  11. McTavish KJ, Nonis D, Hoang YD, Shimasaki S. Granulosa cell tumor mutant FOXL2C134W suppresses GDF-9 and activin A-induced follistatin transcription in primary granulosa cells. Mol Cell Endocrinol. 2013;372:57–64.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Wang XW, Yu Y, Gu L. Dehydroabietic acid reverses TNF-alpha-induced the activation of FOXO1 and suppression of TGF-beta1/Smad signaling in human adult dermal fibroblasts. Int J Clin Exp Pathol. 2014;7:8616–26.PubMedPubMed CentralGoogle Scholar
  13. Irusta G, Pazos MC, Abramovich D, De Zuniga I, Parborell F, Tesone M. Effects of an inhibitor of the gamma-secretase complex on proliferation and apoptotic parameters in a FOXL2-mutated granulosa tumor cell line (KGN). Biol Reprod. 2013;89:9.View ArticlePubMedGoogle Scholar
  14. Schmidt D, Ovitt CE, Anlag K, Fehsenfeld S, Gredsted L, Treier AC, Treier M. The murine winged-helix transcription factor Foxl2 is required for granulosa cell differentiation and ovary maintenance. Development. 2004;131:933–42.View ArticlePubMedGoogle Scholar
  15. Shah SP, Kobel M, Senz J, Morin RD, Clarke BA, Wiegand KC, Leung G, Zayed A, Mehl E, Kalloger SE, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med. 2009;360:2719–29.View ArticlePubMedGoogle Scholar
  16. Suh DS, Oh HK, Kim JH, Park S, Shin E, Lee K, Kim YH, Bae J. Identification and validation of differential Phosphorylation sites of the nuclear FOXL2 protein as potential novel biomarkers for adult-type Granulosa cell tumors. J Proteome Res. 2015;14:2446–56.View ArticlePubMedGoogle Scholar
  17. Benayoun BA, Kalfa N, Sultan C, Veitia RA. The forkhead factor FOXL2: a novel tumor suppressor? Biochim Biophys Acta. 2010;1805:1–5.PubMedGoogle Scholar
  18. Kalfa N, Philibert P, Patte C, Ecochard A, Duvillard P, Baldet P, Jaubert F, Fellous M, Sultan C. Extinction of FOXL2 expression in aggressive ovarian granulosa cell tumors in children. Fertil Steril. 2007;87:896–901.View ArticlePubMedGoogle Scholar
  19. Kim JH, Kim YH, Kim HM, Park HO, Ha NC, Kim TH, Park M, Lee K, Bae J. FOXL2 posttranslational modifications mediated by GSK3beta determine the growth of granulosa cell tumours. Nat Commun. 2014;5:2936.PubMedGoogle Scholar
  20. Benayoun BA, Caburet S, Dipietromaria A, Georges A, D'Haene B, Pandaranayaka PJ, L'Hote D, Todeschini AL, Krishnaswamy S, Fellous M, et al. Functional exploration of the adult ovarian granulosa cell tumor-associated somatic FOXL2 mutation p.Cys134Trp (c.402C>G). PLoS One. 2010;5:e8789.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Farkkila A, Haltia UM, Tapper J, McConechy MK, Huntsman DG, Heikinheimo M. Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary. Ann Med. 2017;49:435–47.View ArticlePubMedGoogle Scholar
  22. Rosario R, Araki H, Print CG, Shelling AN. The transcriptional targets of mutant FOXL2 in granulosa cell tumours. PLoS One. 2012;7:e46270.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Rosario R, Cohen PA, Shelling AN. The role of FOXL2 in the pathogenesis of adult ovarian granulosa cell tumours. Gynecol Oncol. 2014;133:382–7.View ArticlePubMedGoogle Scholar
  24. Kim JH, Yoon S, Park M, Park HO, Ko JJ, Lee K, Bae J. Differential apoptotic activities of wild-type FOXL2 and the adult-type granulosa cell tumor-associated mutant FOXL2 (C134W). Oncogene. 2011;30:1653–63.View ArticlePubMedGoogle Scholar
  25. Cheng JC, Klausen C, Leung PC. Overexpression of wild-type but not C134W mutant FOXL2 enhances GnRH-induced cell apoptosis by increasing GnRH receptor expression in human granulosa cell tumors. PLoS One. 2013;8:e55099.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Cheng JC, Chang HM, Qiu X, Fang L, Leung PC. FOXL2-induced follistatin attenuates activin A-stimulated cell proliferation in human granulosa cell tumors. Biochem Biophys Res Commun. 2014;443:537–42.View ArticlePubMedGoogle Scholar
  27. Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer. 2011;11:338–51.View ArticlePubMedGoogle Scholar
  28. Masek J, Andersson ER. The developmental biology of genetic notch disorders. Development. 2017;144:1743–63.View ArticlePubMedGoogle Scholar
  29. Terauchi KJ, Shigeta Y, Iguchi T, Sato T. Role of notch signaling in granulosa cell proliferation and polyovular follicle induction during folliculogenesis in mouse ovary. Cell Tissue Res. 2016;365:197–208.View ArticlePubMedGoogle Scholar
  30. Budi EH, Duan D, Derynck R. Transforming growth factor-beta receptors and Smads: regulatory complexity and functional versatility. Trends Cell Biol. 2017;27:658–62.Google Scholar
  31. Massague J. TGFbeta signalling in context. Nat Rev Mol Cell Biol. 2012;13:616–30.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Pangas SA. Bone morphogenetic protein signaling transcription factor (SMAD) function in granulosa cells. Mol Cell Endocrinol. 2012;356:40–7.Google Scholar
  33. Thompson TB, Cook RW, Chapman SC, Jardetzky TS, Woodruff TK. Beta A versus beta B: is it merely a matter of expression? Mol Cell Endocrinol. 2004;225:9–17.View ArticlePubMedGoogle Scholar
  34. Makanji Y, Zhu J, Mishra R, Holmquist C, Wong WP, Schwartz NB, Mayo KE, Woodruff TK. Inhibin at 90: from discovery to clinical application, a historical review. Endocr Rev. 2014;35:747–94.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Ethier JF, Findlay JK. Roles of activin and its signal transduction mechanisms in reproductive tissues. Reproduction. 2001;121:667–75.View ArticlePubMedGoogle Scholar
  36. Looyenga BD, Wiater E, Vale W, Hammer GD. Inhibin-A antagonizes TGFbeta2 signaling by down-regulating cell surface expression of the TGFbeta coreceptor betaglycan. Mol Endocrinol. 2010;24:608–20.View ArticlePubMedGoogle Scholar
  37. McCullagh DR. Dual endocrine activity of the testes. Science. 1932;76:19–20.View ArticlePubMedGoogle Scholar
  38. Matzuk MM, Finegold MJ, Su JG, Hsueh AJ, Bradley A. Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature. 1992;360:313–9.View ArticlePubMedGoogle Scholar
  39. Kadariya I, Wang J, ur Rehman Z, Ali H, Riaz H, He J, Bhattarai D, Liu JJ, Zhang SJ. RNAi-mediated knockdown of inhibin alpha subunit increased apoptosis in granulosa cells and decreased fertility in mice. J Steroid Biochem Mol Biol. 2015;152:161–70.View ArticlePubMedGoogle Scholar
  40. Suresh PS, Rajan T, Tsutsumi R. New targets for old hormones: inhibins clinical role revisited. Endocr J. 2011;58:223–35.View ArticlePubMedGoogle Scholar
  41. Myers M, Middlebrook BS, Matzuk MM, Pangas SA. Loss of inhibin alpha uncouples oocyte-granulosa cell dynamics and disrupts postnatal folliculogenesis. Dev Biol. 2009;334:458–67.View ArticlePubMedPubMed CentralGoogle Scholar
  42. Bilandzic M, Chu S, Farnworth PG, Harrison C, Nicholls P, Wang Y, Escalona RM, Fuller PJ, Findlay JK, Stenvers KL. Loss of betaglycan contributes to the malignant properties of human granulosa tumor cells. Mol Endocrinol. 2009;23:539–48.View ArticlePubMedPubMed CentralGoogle Scholar
  43. Burger HG, Fuller PJ, Chu S, Mamers P, Drummond A, Susil B, Neva P, Robertson DM. The inhibins and ovarian cancer. Mol Cell Endocrinol. 2001;180:145–8.View ArticlePubMedGoogle Scholar
  44. Fuller PJ, Zumpe ET, Chu S, Mamers P, Burger HG. Inhibin-activin receptor subunit gene expression in ovarian tumors. J Clin Endocrinol Metab. 2002;87:1395–401.View ArticlePubMedGoogle Scholar
  45. Oktem O, Akin N, Bildik G, Yakin K, Alper E, Balaban B, Urman B. FSH stimulation promotes progesterone synthesis and output from human granulosa cells without luteinization. Hum Reprod. 2017;32:643–52.View ArticlePubMedGoogle Scholar
  46. Kim SY, Ebbert K, Cordeiro MH, Romero MM, Whelan KA, Suarez AA, Woodruff TK, Kurita T. Constitutive activation of PI3K in oocyte induces ovarian Granulosa cell tumors. Cancer Res. 2016;76:3851–61.View ArticlePubMedPubMed CentralGoogle Scholar
  47. Robertson DM, Cahir N, Burger HG, Mamers P, Groome N. Inhibin forms in serum from postmenopausal women with ovarian cancers. Clin Endocrinol. 1999;50:381–6.View ArticleGoogle Scholar
  48. Vihko KK, Blauer M, Puistola U, Tuohimaa P. Activin B in patients with granulosa cell tumors: serum levels in comparison to inhibin. Acta Obstet Gynecol Scand. 2003;82:570–4.View ArticlePubMedGoogle Scholar
  49. Geerts I, Vergote I, Neven P, Billen J. The role of inhibins B and antimullerian hormone for diagnosis and follow-up of granulosa cell tumors. Int J Gynecol Cancer. 2009;19:847–55.View ArticlePubMedGoogle Scholar
  50. Robertson DM, Stephenson T, Pruysers E, Burger HG, McCloud P, Tsigos A, Groome N, Mamers P, McNeilage J, Jobling T, Healy D. Inhibins/activins as diagnostic markers for ovarian cancer. Mol Cell Endocrinol. 2002;191:97–103.View ArticlePubMedGoogle Scholar
  51. ten Dijke P, Fu J, Schaap P, Roelen BA. Signal transduction of bone morphogenetic proteins in osteoblast differentiation. J Bone Joint Surg Am. 2003;85-A(Suppl 3):34–8.View ArticleGoogle Scholar
  52. Reddi AH, Reddi A. Bone morphogenetic proteins (BMPs): from morphogens to metabologens. Cytokine Growth Factor Rev. 2009;20:341–2.View ArticlePubMedGoogle Scholar
  53. Kouroukis T, Meyer R, Benger A, Marcellus D, Foley R, Browman G. An evaluation of age-related differences in quality of life preferences in patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 2004;45:2471–6.View ArticlePubMedGoogle Scholar
  54. Tripurani SK, Cook RW, Eldin KW, Pangas SA. BMP-specific SMADs function as novel repressors of PDGFA and modulate its expression in ovarian granulosa cells and tumors. Oncogene. 2013;32:3877–85.View ArticlePubMedGoogle Scholar
  55. Edson MA, Nalam RL, Clementi C, Franco HL, Demayo FJ, Lyons KM, Pangas SA, Matzuk MM. Granulosa cell-expressed BMPR1A and BMPR1B have unique functions in regulating fertility but act redundantly to suppress ovarian tumor development. Mol Endocrinol. 2010;24:1251–66.View ArticlePubMedPubMed CentralGoogle Scholar
  56. Van Nieuwenhuysen E, Lambrechts S, Lambrechts D, Leunen K, Amant F, Vergote I. Genetic changes in nonepithelial ovarian cancer. Expert Rev Anticancer Ther. 2013;13:871–82.View ArticlePubMedGoogle Scholar
  57. Miyoshi T, Otsuka F, Suzuki J, Takeda M, Inagaki K, Kano Y, Otani H, Mimura Y, Ogura T, Makino H. Mutual regulation of follicle-stimulating hormone signaling and bone morphogenetic protein system in human granulosa cells. Biol Reprod. 2006;74:1073–82.View ArticlePubMedGoogle Scholar
  58. Shimasaki S, Zachow RJ, Li D, Kim H, Iemura S, Ueno N, Sampath K, Chang RJ, Erickson GF. A functional bone morphogenetic protein system in the ovary. Proc Natl Acad Sci U S A. 1999;96:7282–7.View ArticlePubMedPubMed CentralGoogle Scholar
  59. Lee WS, Otsuka F, Moore RK, Shimasaki S. Effect of bone morphogenetic protein-7 on folliculogenesis and ovulation in the rat. Biol Reprod. 2001;65:994–9.View ArticlePubMedGoogle Scholar
  60. Cui X, Jing X, Wu X, Bi X, Liu J, Long Z, Zhang X, Zhang D, Jia H, Su D, Huo K. Abnormal expression levels of BMP15/Smad1 are associated with granulosa cell apoptosis in patients with polycystic ovary syndrome. Mol Med Rep. 2017;16:8231–6.View ArticlePubMedGoogle Scholar
  61. Chang HL, Pahlavan N, Halpern EF, MacLaughlin DT. Serum Mullerian inhibiting substance/anti-Mullerian hormone levels in patients with adult granulosa cell tumors directly correlate with aggregate tumor mass as determined by pathology or radiology. Gynecol Oncol. 2009;114:57–60.View ArticlePubMedPubMed CentralGoogle Scholar
  62. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, Kramer P, Fauser BC, Themmen AP. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004;10:77–83.View ArticlePubMedGoogle Scholar
  63. Anttonen M, Unkila-Kallio L, Leminen A, Butzow R, Heikinheimo M. High GATA-4 expression associates with aggressive behavior, whereas low anti-Mullerian hormone expression associates with growth potential of ovarian granulosa cell tumors. J Clin Endocrinol Metab. 2005;90:6529–35.View ArticlePubMedGoogle Scholar
  64. Anttonen M, Farkkila A, Tauriala H, Kauppinen M, Maclaughlin DT, Unkila-Kallio L, Butzow R, Heikinheimo M. Anti-Mullerian hormone inhibits growth of AMH type II receptor-positive human ovarian granulosa cell tumor cells by activating apoptosis. Lab Investig. 2011;91:1605–14.View ArticlePubMedGoogle Scholar
  65. Li Q. Inhibitory SMADs: potential regulators of ovarian function. Biol Reprod. 2015;92:50.View ArticlePubMedGoogle Scholar
  66. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996;271:350–3.View ArticlePubMedGoogle Scholar
  67. Pangas SA, Li X, Robertson EJ, Matzuk MM. Premature luteinization and cumulus cell defects in ovarian-specific Smad4 knockout mice. Mol Endocrinol. 2006;20:1406–22.View ArticlePubMedGoogle Scholar
  68. Fortin J, Boehm U, Deng CX, Treier M, Bernard DJ. Follicle-stimulating hormone synthesis and fertility depend on SMAD4 and FOXL2. FASEB J. 2014;28:3396–410.View ArticlePubMedPubMed CentralGoogle Scholar
  69. Yu C, Zhang YL, Fan HY. Selective Smad4 knockout in ovarian preovulatory follicles results in multiple defects in ovulation. Mol Endocrinol. 2013;27:966–78.View ArticlePubMedPubMed CentralGoogle Scholar
  70. Zhang L, Du X, Wei S, Li D, Li Q. A comprehensive transcriptomic view on the role of SMAD4 gene by RNAi-mediated knockdown in porcine follicular granulosa cells. Reproduction. 2016;152:81–9.View ArticlePubMedGoogle Scholar
  71. Miao ZL, Wang ZN, Cheng LQ, Zhang Y. Expression of Smad4 during rat ovarian development. Di Yi Jun Yi Da Xue Xue Bao. 2005;25:127–31.PubMedGoogle Scholar
  72. Coutts SM, Childs AJ, Fulton N, Collins C, Bayne RA, McNeilly AS, Anderson RA. Activin signals via SMAD2/3 between germ and somatic cells in the human fetal ovary and regulates kit ligand expression. Dev Biol. 2008;314:189–99.View ArticlePubMedGoogle Scholar
  73. Mansouri-Attia N, Tripurani SK, Gokul N, Piard H, Anderson ML, Eldin K, Pangas SA. TGFbeta signaling promotes juvenile granulosa cell tumorigenesis by suppressing apoptosis. Mol Endocrinol. 2014;28:1887–98.View ArticlePubMedPubMed CentralGoogle Scholar
  74. Bilandzic M, Chu S, Wang Y, Tan HL, Fuller PJ, Findlay JK, Stenvers KL. Betaglycan alters NFkappaB-TGFbeta2 cross talk to reduce survival of human granulosa tumor cells. Mol Endocrinol. 2013;27:466–79.View ArticlePubMedPubMed CentralGoogle Scholar
  75. Mancari R, Portuesi R, Colombo N. Adult granulosa cell tumours of the ovary. Curr Opin Oncol. 2014;26:536–41.View ArticlePubMedGoogle Scholar
  76. Fuller PJ, Leung D, Chu S. Genetics and genomics of ovarian sex cord-stromal tumors. Clin Genet. 2017;91:285–91.View ArticlePubMedGoogle Scholar
  77. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129:1261–74.View ArticlePubMedPubMed CentralGoogle Scholar
  78. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 1994;78:59–66.View ArticlePubMedGoogle Scholar
  79. Cunningham MA, Zhu Q, Hammond JM. FoxO1a can alter cell cycle progression by regulating the nuclear localization of p27kip in granulosa cells. Mol Endocrinol. 2004;18:1756–67.View ArticlePubMedGoogle Scholar
  80. von Karstedt S, Montinaro A, Walczak H. Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nat Rev Cancer. 2017;17:352–66.View ArticlePubMedGoogle Scholar
  81. Zhang X, Tang N, Hadden TJ, Rishi AK. Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta. 2011;1813:1978–86.View ArticlePubMedGoogle Scholar
  82. Ausserlechner MJ, Salvador C, Deutschmann A, Bodner M, Viola G, Bortolozzi R, Basso G, Hagenbuchner J, Obexer P. Therapy-resistant acute lymphoblastic leukemia (ALL) cells inactivate FOXO3 to escape apoptosis induction by TRAIL and Noxa. Oncotarget. 2013;4:995–1007.View ArticlePubMedPubMed CentralGoogle Scholar
  83. Liu Z, Ren YA, Pangas SA, Adams J, Zhou W, Castrillon DH, Wilhelm D, Richards JS. FOXO1/3 and PTEN depletion in Granulosa cells promotes ovarian Granulosa cell tumor development. Mol Endocrinol. 2015;29:1006–24.View ArticlePubMedPubMed CentralGoogle Scholar
  84. Brandmaier A, Hou SQ, Shen WH. Cell cycle control by PTEN. J Mol Biol. 2017;429:2265–77.View ArticlePubMedGoogle Scholar
  85. Shen W, Li HL, Liu L, Cheng JX. Expression levels of PTEN, HIF-1alpha, and VEGF as prognostic factors in ovarian cancer. Eur Rev Med Pharmacol Sci. 2017;21:2596–603.PubMedGoogle Scholar
  86. Verhagen PC, van Duijn PW, Hermans KG, Looijenga LH, van Gurp RJ, Stoop H, van der Kwast TH, Trapman J. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J Pathol. 2006;208:699–707.View ArticlePubMedGoogle Scholar
  87. Lague MN, Paquet M, Fan HY, Kaartinen MJ, Chu S, Jamin SP, Behringer RR, Fuller PJ, Mitchell A, Dore M, et al. Synergistic effects of Pten loss and WNT/CTNNB1 signaling pathway activation in ovarian granulosa cell tumor development and progression. Carcinogenesis. 2008;29:2062–72.View ArticlePubMedPubMed CentralGoogle Scholar
  88. Kyronlahti A, Ramo M, Tamminen M, Unkila-Kallio L, Butzow R, Leminen A, Nemer M, Rahman N, Huhtaniemi I, Heikinheimo M, Anttonen M. GATA-4 regulates Bcl-2 expression in ovarian granulosa cell tumors. Endocrinology. 2008;149:5635–42.View ArticlePubMedGoogle Scholar
  89. Virgone C, Cecchetto G, Ferrari A, Bisogno G, Donofrio V, Boldrini R, Collini P, Dall'Igna P, Alaggio R. GATA-4 and FOG-2 expression in pediatric ovarian sex cord-stromal tumors replicates embryonal gonadal phenotype: results from the TREP project. PLoS One. 2012;7:e45914.View ArticlePubMedPubMed CentralGoogle Scholar
  90. Kyronlahti A, Kauppinen M, Lind E, Unkila-Kallio L, Butzow R, Klefstrom J, Wilson DB, Anttonen M, Heikinheimo M. GATA4 protects granulosa cell tumors from TRAIL-induced apoptosis. Endocr Relat Cancer. 2010;17:709–17.View ArticlePubMedGoogle Scholar
  91. Durkes A, Garner M, Juan-Salles C, Ramos-Vara J. Immunohistochemical characterization of nonhuman primate ovarian sex cord-stromal tumors. Vet Pathol. 2012;49:834–8.View ArticlePubMedGoogle Scholar
  92. Farkkila A, Pihlajoki M, Tauriala H, Butzow R, Leminen A, Unkila-Kallio L, Heikinheimo M, Anttonen M. Serum vascular endothelial growth factor a (VEGF) is elevated in patients with ovarian granulosa cell tumor (GCT), and VEGF inhibition by bevacizumab induces apoptosis in GCT in vitro. J Clin Endocrinol Metab. 2011;96:E1973–81.View ArticlePubMedGoogle Scholar
  93. Farkkila A, Anttonen M, Pociuviene J, Leminen A, Butzow R, Heikinheimo M, Unkila-Kallio L. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors. Eur J Endocrinol. 2011;164:115–22.View ArticlePubMedGoogle Scholar
  94. Roskoski R Jr. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas. Pharmacol Res. 2017;120:116–32.View ArticlePubMedGoogle Scholar
  95. Karasic TB, Rosen MA, O'Dwyer PJ. Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective? Cancer Chemother Pharmacol. 2017;80:661–71.View ArticlePubMedGoogle Scholar
  96. Tsoi M, Lague MN, Boyer A, Paquet M, Nadeau ME, Boerboom D. Anti-VEGFA therapy reduces tumor growth and extends survival in a Murine model of ovarian Granulosa cell tumor. Transl Oncol. 2013;6:226–33.View ArticlePubMedPubMed CentralGoogle Scholar
  97. Schmidt M, Kammerer U, Segerer S, Cramer A, Kohrenhagen N, Dietl J, Voelker HU. Glucose metabolism and angiogenesis in granulosa cell tumors of the ovary: activation of Akt, expression of M2PK, TKTL1 and VEGF. Eur J Obstet Gynecol Reprod Biol. 2008;139:72–8.View ArticlePubMedGoogle Scholar
  98. Tao X, Sood AK, Deavers MT, Schmeler KM, Nick AM, Coleman RL, Milojevic L, Gershenson DM, Brown J. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol. 2009;114:431–6.View ArticlePubMedPubMed CentralGoogle Scholar
  99. Zhou B, Sun C, Li N, Shan W, Lu H, Guo L, Guo E, Xia M, Weng D, Meng L, et al. Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K/Akt signaling pathways. Int J Oncol. 2016;48:2087–97.View ArticlePubMedGoogle Scholar
  100. Zhang X, Huang X, Fang C, Li Q, Cui J, Sun J, Li L. miR-124 regulates the expression of BACE1 in the hippocampus under chronic cerebral hypoperfusion. Mol Neurobiol. 2017;54:2498–506.View ArticlePubMedGoogle Scholar
  101. Guo L, Zhou B, Liu Z, Xu Y, Lu H, Xia M, Guo E, Shan W, Chen G, Wang C. Blockage of glutaminolysis enhances the sensitivity of ovarian cancer cells to PI3K/mTOR inhibition involvement of STAT3 signaling. Tumour Biol. 2016;37:11007–15.View ArticlePubMedGoogle Scholar

Copyright

Advertisement